Fundraising Fox
/Companies
Sign in

Accession Therapeutics

2 known investors

Find your way into Accession Therapeutics

Sign up to see every warm intro you have to Accession Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Accession Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Accession Therapeutics develops cancer treatments by harnessing immune system mechanisms, with a focus on T cell receptor therapies and engineered cell therapies. The company is led by experienced biotech entrepreneurs and scientific experts with a track record in bringing immunological oncology projects to clinical development.

BiotechHealthtechMedical Devices

Founders & leadership

APAlan Parker
Alan ParkerCSO and Founder of TroceptAlan Parker holds a PhD in Gene Therapy from the University of Birmingham and an undergraduate degree in Genetics from the University of Sheffield. He is CSO of Trocept Therapeutics (part of Accession Therapeutics) and leads a research group at Cardiff University's School of Medicine developing virotherapies for cancer, with expertise in immuno-oncology and translational oncology supported by multiple grants from Cancer Research UK, charities, and UK research councils.
BJBent Jakobsen
Bent JakobsenCEO and Founder

Investors · 2

Birk VenturereportedOslo

How we know: press coverage · Not right? Tell us

In the news

Accession Therapeutics awarded €7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapyaccessiontherapeutics.com · Mar 2026Accession Therapeutics raises £30.5 million ($40 million USD) to advance TROCEPT immunotherapy platformaccessiontherapeutics.com · Dec 2025Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidateaccessiontherapeutics.com · Apr 2024Accession Therapeutics raises £16.6m to advance potent immunotherapies towards clinical trialsaccessiontherapeutics.com · Nov 2022

Frequently asked questions

What does Accession Therapeutics do?
Accession Therapeutics develops cancer treatments by harnessing immune system mechanisms, with a focus on T cell receptor therapies and engineered cell therapies. The company is led by experienced biotech entrepreneurs and scientific experts with a track record in bringing immunological oncology projects to clinical development.
Who founded Accession Therapeutics?
Accession Therapeutics was founded by Alan Parker.
Who are Accession Therapeutics's investors?
Accession Therapeutics's investors include iGlobe Partners, Birk Venture.